Published in Thromb Res on May 15, 1983
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest (1994) 3.51
Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol (2005) 2.56
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest (1995) 1.55
Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci U S A (1994) 1.53
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A (1988) 1.51
Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol (1990) 1.36
The formation of nitric oxide donors from peroxynitrite. Br J Pharmacol (1995) 1.14
Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase. Br J Pharmacol (1991) 1.14
Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol (1989) 1.14
The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol (1990) 1.11
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol (2000) 1.09
Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol (2003) 1.08
Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets. Br J Pharmacol (2002) 1.08
Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol (2002) 1.07
C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci U S A (2005) 1.04
Increased intestinal formation of Paf in endotoxin-induced damage in the rat. Br J Pharmacol (1987) 1.00
Amorphous silica nanoparticles aggregate human platelets: potential implications for vascular homeostasis. Int J Nanomedicine (2012) 0.95
Elucidation of flow-mediated tumour cell-induced platelet aggregation using an ultrasound standing wave trap. Br J Pharmacol (2011) 0.92
Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets. Br J Pharmacol (1994) 0.91
Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin. Br J Pharmacol (2001) 0.91
Pharmacological characteristics of solid-phase von Willebrand factor in human platelets. Br J Pharmacol (2001) 0.90
Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol (2012) 0.89
Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide. Br J Clin Pharmacol (1993) 0.89
Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation. Br J Pharmacol (1989) 0.88
Inhibition of carrageenin-induced rat paw oedema by crotapotin, a polypeptide complexed with phospholipase A2. Br J Pharmacol (1995) 0.87
Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation. Br J Pharmacol (1996) 0.87
Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells. Br J Pharmacol (1993) 0.86
Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505. Br J Pharmacol (1993) 0.86
The acceleration of the inhibition of platelet prothrombinase complex by heparin. Biochem J (1986) 0.84
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels. J Psychiatry Neurosci (2003) 0.83
Effect of carbenoxolone on the biological activity of nitric oxide: relation to gastroprotection. Br J Pharmacol (1991) 0.83
Hydrogen peroxide at low concentrations strongly enhances the inhibitory effect of nitric oxide on platelets. Biochem J (1995) 0.83
The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation. Int J Nanomedicine (2012) 0.82
Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br J Pharmacol (2004) 0.82
Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds. Br J Pharmacol (1992) 0.81
Nitric oxide dysregulation in platelets from patients with advanced Huntington disease. PLoS One (2014) 0.81
Chemical synthesis and structural characterization of the RGD-protein decorsin: a potent inhibitor of platelet aggregation. Protein Sci (1998) 0.79
CdTe quantum dots induce activation of human platelets: implications for nanoparticle hemocompatibility. Int J Nanomedicine (2015) 0.78
Cultured astrocytoma cells generate a nitric oxide-like factor from endogenous L-arginine and glyceryl trinitrate: effect of E. coli lipopolysaccharide. Br J Pharmacol (1992) 0.77
Platelet in vitro responses to urapidil and prazosin. Drugs (1990) 0.77
Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin. Br J Pharmacol (2012) 0.76
Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990. Br J Pharmacol (1990) 0.75
Vascular and anti-platelet actions of 1,2- and 1,3-glyceryl dinitrate. Br J Pharmacol (1993) 0.75
Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies. Br J Pharmacol (1993) 0.75
Incorporation of β-actin loading control into zymography. J Biol Methods (2016) 0.75
Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry. Int J Nanomedicine (2015) 0.75
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79
Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73
Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31
Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun (1990) 2.31
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27
Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol (1999) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24
Nitric oxide synthase activity in human breast cancer. Br J Cancer (1995) 2.22
Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet (1993) 2.20
cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A (1996) 2.17
A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol (1991) 2.15
Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther (1984) 2.12
Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte. Proc Natl Acad Sci U S A (1993) 2.10
Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol (1992) 2.09
Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun (1992) 2.08
Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06
Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet (1990) 2.04
Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A (2001) 2.03
Mechanism of action of some inhibitors of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1986) 2.03
Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01
The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. J Pharm Pharmacol (1983) 2.00
Kinetic characteristics of nitric oxide synthase from rat brain. Biochem J (1990) 2.00
Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo. Cardiovasc Res (1989) 1.98
Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells. Br J Pharmacol (1991) 1.96
The effect of nitric oxide on cell respiration: A key to understanding its role in cell survival or death. Proc Natl Acad Sci U S A (2000) 1.96
Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol (1990) 1.93
The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. Proc Natl Acad Sci U S A (1995) 1.88
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins (1978) 1.85
Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochem J (1990) 1.85
Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85
Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol (1991) 1.84
Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol (1994) 1.82
Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol (1993) 1.79
Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet (1991) 1.78
Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens (1992) 1.77
On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc Natl Acad Sci U S A (1999) 1.76
Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res (1994) 1.74
Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun (1993) 1.73
Regional haemodynamic changes during oral ingestion of NG-monomethyl-L-arginine or NG-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol (1990) 1.72